Pharming Ups 2023 Guidance: RUCONEST® Revenue Jumps 10%, Joenja® Hits $18M

TL;DR

**Pharming just crushed its own 2023 revenue guidance for RUCONEST® and Joenja®!**

AI Summary

Pharming Group N.V. announced updated full-year 2023 guidance on January 8, 2024, projecting a significant 10% growth in RUCONEST® revenue, which is much higher than their previous estimates. They also expect Joenja® revenues to reach approximately US$18 million, with 81 patients on paid therapy by year-end 2023. This positive update suggests stronger-than-expected performance for their key products, which could lead to increased investor confidence and potentially a higher stock valuation for current and prospective shareholders.

Why It Matters

This filing indicates Pharming's core products are performing better than anticipated, which could translate to improved financial health and future growth prospects for the company.

Risk Assessment

Risk Level: low — The filing reports positive updates on revenue guidance and product performance, indicating reduced financial uncertainty for the company.

Analyst Insight

A smart investor would review their position in PHAR, considering the strong performance of key products RUCONEST® and Joenja®, which exceeded prior guidance and could signal sustained growth.

Key Numbers

• 10% — RUCONEST® revenue growth (significantly exceeding prior guidance for full year 2023)
• US$18 million — Joenja® revenues (expected for full year 2023)
• 81 — patients on paid Joenja® therapy (at year-end 2023)
• January 8, 2024 — date of announcement (when the updated guidance was released)

Key Players & Entities

• Pharming Group N.V. (company) — the registrant and issuer of the press release
• Sijmen de Vries (person) — CEO of Pharming Group N.V. who signed the report
• RUCONEST® (company) — a key product with expected 10% revenue growth
• Joenja® (company) — a key product with expected US$18 million in revenues
• US$18 million (dollar_amount) — expected revenues for Joenja®
• 81 (number) — number of patients on paid Joenja® therapy at year-end

Forward-Looking Statements

• Pharming Group N.V.'s stock price will see a positive reaction due to the strong updated guidance. (Pharming Group N.V.) — medium confidence, target: Q1 2024
• Analyst ratings for Pharming Group N.V. will be revised upwards following this positive revenue update. (Pharming Group N.V.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $18 million — pect Joenja revenues of approximately US$18 million with 81 patients on paid therapy at yea
• $245 million — d to increase by 19% to approximately US$245 million (preliminary and unaudited*). Sijmen
• $227 m — s to increase by 10% to approximately US$227 million, significantly exceeding our prev
• $215.0 million — ble securities, are expected to total US$215.0 million at the end of 2023, compared to US$199.
• $199.2 million — llion at the end of 2023, compared to US$199.2 million at the end of the third quarter 2023 an
• $208.7 million — the end of the third quarter 2023 and US$208.7 million at the end of 2022. *Updated guidance

Filing Documents

• businessandguidanceupdate2.htm (6-K) — 34KB
• logo_greyxoriginalx.jpg (GRAPHIC) — 112KB
• 0001628280-24-000782.txt ( ) — 177KB

Forward-looking Statements

Forward-looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", anticipate'', believe'', could'', estimate'', expect'', goals'', intend'', may'', "milestones", objectives'', outlook'', plan'', probably'', project'', risks'', "schedule", seek'', should'', target'', will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2022 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Reader

View Full Filing

View this 6-K filing on SEC EDGAR